Physician profile
Steven Colucci
NPI 1285674309
$8,892.11
in general payments reported to CMS, 2019-2025
34 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $999 · 2020: $609 · 2021: $929 · 2022: $1,591 · 2023: $1,725 · 2024: $1,621 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,764.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,475.48 | 2019-2025 | |
| Novo Nordisk INC | $882.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $873.03 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Dexcom, INC. | $548.62 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $527.90 | 2019-2025 | |
| Abbvie INC. | $519.35 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.46 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $447.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $347.01 | 2022-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $323.19 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $288.96 | 2019-2025 | Belsomra, Steglatro, Verquvo |
| Glaxosmithkline, LLC. | $285.12 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.40 | 2021-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $227.44 | 2024-2025 | Voquezna |
| Amgen INC. | $212.62 | 2019-2023 | Repatha, Otezla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $190.26 | 2019-2023 | |
| Abbott Laboratories | $173.08 | 2019-2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $160.51 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $158.03 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $98.53 | 2023-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $88.51 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.92 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $61.40 | 2021 | |
| Exact Sciences Corporation | $44.23 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $31.77 | 2022-2025 | |
| Allergan, INC. | $22.45 | 2020 | |
| Lundbeck LLC | $21.93 | 2025 | Rexulti |
| Amarin Pharma, INC. | $18.35 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.01 | 2019 | |
| Esperion Therapeutics, INC. | $15.34 | 2021 | |
| Averitas Pharma INC. | $14.77 | 2025 | Qutenza |
| Idorsia Pharmaceuticals US INC | $13.51 | 2022 | |
| Daiichi Sankyo INC. | $12.83 | 2022 | |
| Nabriva Therapeutics, Plc | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Colucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.